Arbutus Biopharma Corporation
ABUS
$3.29
-$0.05-1.50%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 4.02% | -1.63% | -5.70% | -6.22% | -4.89% |
| Total Depreciation and Amortization | -1.71% | 3.99% | 8.52% | 4.24% | -1.61% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 74.21% | -2.32% | 45.04% | 17.64% | 9.10% |
| Change in Net Operating Assets | 84.48% | 93.13% | 85.97% | 50.89% | -162.35% |
| Cash from Operations | 24.54% | 16.12% | 11.71% | 6.42% | -143.06% |
| Capital Expenditure | 81.94% | 91.59% | 89.34% | -77.98% | -96.88% |
| Sale of Property, Plant, and Equipment | -- | -- | 200.00% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -55.31% | -24.81% | 196.90% | 1,892.97% | 169.54% |
| Cash from Investing | -54.80% | -22.96% | 217.51% | 2,455.19% | 167.75% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 69.66% | 43.40% | 19.64% | -14.94% | -3.67% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 69.66% | 43.40% | 19.64% | -14.94% | -3.67% |
| Foreign Exchange rate Adjustments | -296.00% | -128.57% | 105.26% | 144.44% | 213.64% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 323.67% | 321.15% | 276.87% | 106.20% | 94.28% |